Generalized Myasthenia Gravis Drug Receives EU Approval

The European Commission has granted market authorization for efgartigimod (Vyvgart, argenx) as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti–acetylcholine receptor (AChR) antibody. The drug was approved

What is the impact of COVID-19 on male reproductive health?

In a recent study published in the Journal of Endocrinological Investigation, researchers assessed male reproductive health three months after coronavirus disease 2019 (COVID-19) infection. Study: Male reproductive health after 3 months from SARS-CoV-2 infection: a